At what enterprise value was IMV TECHNOLOGIES acquired in 2021?

During the acquisition of IMV TECHNOLOGIES by MONTAGU PRIVATE EQUITY in 2021, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of IMV TECHNOLOGIES when it was acquired by MONTAGU PRIVATE EQUITY?

The estimated EV/EBITDA multiple for IMV TECHNOLOGIES is in the range of 10x - 18x.

When was IMV TECHNOLOGIES acquired by MONTAGU PRIVATE EQUITY?

IMV TECHNOLOGIES was acquired by MONTAGU PRIVATE EQUITY in 2021.

What was the revenue of IMV TECHNOLOGIES at the time of the deal?

The revenue of IMV TECHNOLOGIES at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of IMV TECHNOLOGIES during the acquisition?

IMV TECHNOLOGIES's EBITDA is estimated to be in the range of 10M - 30M EUR.

How is the data for the IMV TECHNOLOGIES acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the IMV TECHNOLOGIES deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://montagu.com/montagu-enters-exclusive-negotiations-to-acquire-imv-technologies/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaIMV TECHNOLOGIES

01/2021

IMV TECHNOLOGIES acquired by MONTAGU PRIVATE EQUITY

FRANCE Life Sciences / Pharma & Biotech / R&D Biotech EV 300M - 700M EUR

Context

Montagu Private Equity entered into exclusive negotiations to acquire a majority stake in IMV Technologies from Qualium Investissement. Montagu prevailed in a competitive process against CVC Capital Partners. This transaction marks the fifth LBO for the company, which was previously backed by Idi, Ofi Private Equity, and Sparring Capital. The deal underpins the company's leadership in the niche market of animal genetics and its strong export capabilities.

In the past, the company had already been the subject of several LBOs, notably led by Sparring Capital in 2010 and Qualium in 2014. This succession of buyouts highlights the strong attractiveness of the company's business model.

IMV TECHNOLOGIES, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

IMV Technologies is the world leader in reproduction biotechnologies for livestock (primarily bovine and porcine). The company designs and manufactures equipment and consumables (plastic straws) for artificial insemination. It holds a dominant position with over 50% global market share in bovine packaging. 85% of its revenue is generated internationally across 120 countries.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with IMV TECHNOLOGIES

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
11/2014	QUALIUM	IMV TECHNOLOGIES	FRANCE	R&D Biotech
09/2010	SPARRING CAPITAL	IMV TECHNOLOGIES	FRANCE	R&D Biotech

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of IMV TECHNOLOGIES by MONTAGU PRIVATE EQUITY are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: imv technologies

Acquirer: montagu private equity